HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)

Histopathology

Volumn 58, Issue 3, 2011, Pages 383-394

  Boers, James E ^a   Meeuwissen, Harriëtte ^a   Methorst, Natalie ^a  

^a Pathology   (Netherlands)

Author keywords

Anti HER2 therapy; Gastric adenocarcinoma; HER2; Immunohistochemistry; In situ hybridization; Oesophageal adenocarcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4B5; SP3 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SILVER IN SITU HYBRIDIZATION; STOMACH ADENOCARCINOMA; TUMOR BIOPSY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ESOPHAGEAL NEOPLASMS; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; SILVER; STOMACH NEOPLASMS;

ORYCTOLAGUS CUNICULUS;

EID: 79952079704     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03760.x     Document Type: Article

References (38)

1. Marx AH, Tharun L, Muth J et al. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 2009; 40; 769-777.
2. Bang YJ, Chung HC, Sawaki S et al. HER2-positivity rates in advanced gastric cancer: results from a large international phase III trial. J. Clin. Oncol. 2008; 26; 219s.
3. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52; 797-805.
4. Reichelt U, Duesedau P, Tsourlakis M et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod. Pathol. 2007; 20; 120-129.
5. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001; 19; 554-568.
6. Tapia C, Glatz K, Novotny H et al. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod. Pathol. 2007; 20; 192-198.
7. Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum. Pathol. 2006; 37; 1333-1343.
8. Kim MA, Jung EJ, Lee HS et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum. Pathol. 2007; 38; 1386-1393.
9. Park DI, Yun JW, Park JH et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig. Dis. Sci. 2006; 51; 1371-1379.
10. Miller CT, Moy JR, Lin L et al. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin. Cancer Res. 2003; 9; 4819-4825.
11. Tanner M, Hollmen M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005; 16; 273-278.
12. Flejou JF, Paraf F, Muzeau F et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J. Clin. Pathol. 1994; 47; 23-26.
13. Tsugawa K, Fushida S, Yonemura Y. Amplification of the c-erbB-2 gene in gastric carcinoma: correlation with survival. Oncology 1993; 50; 418-425.
14. Takehana T, Kunitomo K, Kono K et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int. J. Cancer 2002; 98; 833-837.
15. Motojima K, Furui J, Kohara N, Izawa K, Kanematsu T, Shiku H. erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery 1994; 115; 349-354.
16. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum. Pathol. 2000; 31; 35-39.
17. Jaehne J, Urmacher C, Thaler HT, Friedlander-Klar H, Cordon-Cardo C, Meyer HJ. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J. Cancer Res. Clin. Oncol. 1992; 118; 474-479.
18. Risio M, De Rosa G, Sarotto I et al. HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int. J. Oncol. 2003; 23; 1381-1387.
19. Barros-Silva JD, Leitao D, Afonso L et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br. J. Cancer 2009; 100; 487-493.
20. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376; 687-697.
21. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist 2005; 10; 590-601.
22. Hamilton SR, Aaltonen LA. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000.
23. Enzinger PC, Mayer RJ. Esophageal cancer. N. Engl. J. Med. 2003; 349; 2241-2252.
24. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann. Surg. 2005; 241; 27-39.
25. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007; 131; 18.
26. Milanezi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev. Mol. Diagn. 2008; 8; 417-434.
27. Sheppard B. Results of the College of American Pathologists HER2 proficiency exam. BioPerspectives - the Ventana Newsletter: Tucson, AZ: Ventana Medical Systems Inc., 2007.
28. Ricardo SA, Milanezi F, Carvalho ST, Leitao DR, Schmitt FC. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J. Clin. Pathol. 2007; 60; 1001-1005.
29. Dietel M, Ellis IO, Hofler H et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007; 451; 19-25.
30. Nunes CB, Rocha RM, Reis-Filho JS et al. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J. Clin. Pathol. 2008; 61; 934-938.
31. Walker RA, Bartlett JM, Dowsett M et al. HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 2008; 61; 818-824.
32. Nordiqc. Assessment Run B6 2008. Available at: ed. Acessed January 15, 2009.
33. Powell WC, Hicks DG, Prescott N et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 94-102.
34. Egervari K, Szollosi Z, Nemes Z. Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study. Tumour Biol. 2008; 29; 18-27.
35. Capizzi E, Gruppioni E, Grigioni AD et al. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry. Diagn. Mol. Pathol. 2008; 17; 220-226.
36. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am. J. Pathol. 1997; 151; 761-768.
37. Varis A, Zaika A, Puolakkainen P et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int. J. Cancer 2004; 109; 548-553.
38. Yano T, Doi T, Ohtsu A et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol. Rep. 2006; 15; 65-71.